MYC and liver cancer: Furthermore, the combination of Sorafenib and CPSF6 depletion significantly enhanced cytotoxicity and the G1 population and suppressed the expression of c-Myc, pro-PARP and pro-caspase3 compared to sorafenib alone in Hep3B cells, strongly demonstrating the synergistic potential of CPSF6 depletion with sorafenib for liver cancer therapy.